# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically sign...
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that ...
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
HC Wainwright & Co. analyst Joseph Pantginis maintains Palatin Techs (AMEX:PTN) with a Buy, adjusts target to $17 from $70.
Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondar...
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market o...